Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection

2021; Taylor & Francis; Volume: 115; Issue: 4 Linguagem: Inglês

10.1080/20477724.2021.1890887

2047-7732

Luis Enrique Bermejo Galan, Nayara Melo dos Santos, Mauro Shosuka Asato, Jucineide Vieira Araújo, Adriana de Lima Moreira, Aléxia Mahara Marques Araújo, Artur Diogenes Pinheiro Paiva, Diego Guilherme Santos Portella, Frank Silas Saldanha Marques, Gabriel M. Alexandre-Silva, Joana de Sousa Resende, Marycassiely Rodrigues Tizolim, Poliana Lucenados Santos, Steffi Ferreira Buttenbender, Stephanye Batista de Andrade, Roberto Carlos Cruz Carbonell, Juliana Gomes Da Rocha, Ruy Guilherme Silveira de Souza, Allex Jardim da Fonseca,

Antibiotic Use and Resistance

Objective: Given the urgent need for strategies to minimize the damage caused by this pandemic, this study performed a randomized, double-blind phase 2 study to assess the safety of the effectiveness of chloroquine (CQ), hydroxychloroquine (HCQ) or ivermectin in severe forms of COVID-19, in addition to identifying predictors of mortality in this group of patients.